“Real world” study of antipsychotic effectiveness for chronic inpatients with schizophrenia in a state psychiatric hospital: Preliminary results and commentary

References

• Bekelman J. E., Li Y., Gross C. P. Scope and impact of financial conflicts of interest in biomedical research. Journal of the American Medical Association 2003; 289: 454–465
   PubMed Web of Science ®Google Scholar
• Bodenheimer T. Clinical investigators and the pharmaceutical industry. New England Journal of Medicine 2000; 342: 1539–1544
   PubMed Web of Science ®Google Scholar
• Bowen J., Hirsch S. Recruitment rates and factors affecting recruitments for a clinical trial of a putative anti-psychotic agent in the treatment of acute schizophrenia. Human Psychopharmacology 1992; 7: 337–341
   Web of Science ®Google Scholar
• Carpenter W. T., Jr, Gold J. M. Another view of therapy for cognition in schizophrenia. Biological Psychiatry 2002; 5: 969–971
   Google Scholar
• Carpenter W. T., Jr, Gold J. M., Lahti A. C., Queern C. A., Conley R. R., Bartko J. J., Kovnick J., Appelbaum P. S. Decisional capacity for informed consent in schizophrenia research. Archives of General Psychiatry 2000; 57: 533–538
   PubMed Web of Science ®Google Scholar
• Chakos M., Lieberman J., Hoffman E., Bradford D., Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: A review and meta-analysis of randomized trials. American Journal of Psychiatry 2001; 158: 518–526
   PubMed Web of Science ®Google Scholar
• Clark R. E., Bartels S. J., Mellman T. A., Peacock W. J. Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: Implications for state mental health policy. Schizophrenia Bulletin 2002; 28: 75–84
   PubMed Web of Science ®Google Scholar
• Csernansky J. G., Schuchart E. K. Relapse and rehospitalization rates in patients with schizophrenia. CNS Drugs 2002; 16: 473–484
   PubMed Web of Science ®Google Scholar
• Davis J. M., Chen N., Glick I. D. A meta-analysis of the efficacy of second-generation antipsychotics. Archives of General Psychiatry 2003; 60: 553–564
   PubMed Web of Science ®Google Scholar
• Dolder C. R., Lacro J. P., Dunn L. B., Jeste D. V. Antipsychotic medication adherence: Is there a difference between typical and atypical agents?. American Journal of Psychiatry 2002; 159: 103–108
   PubMed Web of Science ®Google Scholar
• Fleishman M. Issues in psychopharmacosocioeconomics. Psychiatric Services 2002; 53: 1532–1534
   PubMedGoogle Scholar
• Fleishman M. Psychopharmacosocioeconomics and the global burden of disease. Psychiatric Services 2003; 54: 142–144
   PubMedGoogle Scholar
• Geddes J., Freemantle N., Harrison P., for the National Schizophrenia Guideline Group. Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis. British Medical Journal 2000; 312: 1371–1376
   Google Scholar
• Hofer A., Hummer M., Huber R., Kurz M., Walch T., Fleischhacker W. W. Selection bias in clinical trials with antipsychotics. Journal of Clinical Psychopharmacology 2000; 20: 699–702
   PubMed Web of Science ®Google Scholar
• Johns M. M. E., Barnes M., Florencio P. S. Restoring balance to industry-academia relationships in an era of institutional financial conflicts of interest. Journal of the American Medical Association 2003; 289: 741–746
   Google Scholar
• Leucht S., Barnes T. R. E., Kissling W., Engel R. R., Correll C., Kane J. M. Relapse prevention in schizophrenia with new-generation antipsychotics: A systematic review and exploratory meta-analysis of randomized, controlled trails. American Journal of Psychiatry 2003; 160: 1209–1222
   PubMed Web of Science ®Google Scholar
• Leucht S., Wahlbeck K., Hamann J., Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: A systematic review and meta-analysis. Lancet 2003; 361: 1581–1589
   PubMed Web of Science ®Google Scholar
• Morin K., Rakatansky H., Riddick F. A., Morse L. J., O'Bannon J. M., Goldrich M. S., Ray P., Weiss M., Sade R. M., Spillman M. A. Managing conflicts of interest in the conduct of clinical trials. Journal of the American Medical Association 2002; 287: 78–84
   PubMed Web of Science ®Google Scholar
• Newcomer J. W., Haupt D. W., Fucetola R., Melson A. K., Schweiger J. A., Cooper B. P., Selke G. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Archives of General Psychiatry 2002; 59: 337–345
   PubMed Web of Science ®Google Scholar
• Roberts L. W., Warner T. D., Brody J. L., Roberts B., Lauriello J., Lyketsos C. Patient and psychiatrist ratings of hypothetical schizophrenia research protocols: Assessment of harm potential and factors influencing participation decisions. American Journal of Psychiatry 2002; 159: 573–584
   PubMed Web of Science ®Google Scholar
• Robinson D., Woerner M. G., Pollack S., Lerner G. Subject selection biases in clinical trials: data from a multicenter schizophrenia treatment study. Journal of Clinical Psychopharmacology 1996; 16: 170–176
   PubMed Web of Science ®Google Scholar
• Rosenheck R., Perlick D., Bingham S., Liu-Mares W., Collins J., Warren S., Leslie D., Allan E., Campbell E. C., Caroff S., Corwin J., Davis L., Douyon R., Dunn L., Evans D., Frecska R. E., Grabowski J., Graeber D., Herz L., Kwon K., Lawson W., Mena F., Sheikh J., Smelson D., Smith-Gamble V., for the Department of Veterans Affairs Cooperative Study. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia. Journal of the American Medical Association 2003; 290: 2693–2702
   PubMed Web of Science ®Google Scholar
• Sernyak M. J., Leslie D. L., Alarcon R. D., Losonczy M. F., Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. American Journal of Psychiatry 2002; 159: 561–566
   PubMed Web of Science ®Google Scholar
• Stanniland C., Taylor D. Tolerability of atypical antipsychotics. Drug Safety 2000; 22: 196–214
   Google Scholar
• Stiles P. G., Poythress N. G., Hall A., Falkenback D., Williams R. Improving understanding of research consent disclosures among persons with mental illness. Psychiatric Services 2001; 52: 780–785
   PubMed Web of Science ®Google Scholar
• Tapp A., Wood A. E., Secrest L., Erdmann J., Cubberley L., Kilzieh N. Combination antipsychotic therapy in clinical practice. Psychiatric Services 2003; 54: 55–59
   PubMed Web of Science ®Google Scholar
• Tarsy D., Baldessarini R. J., Tarazi F. I. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 2002; 16: 23–45
   PubMed Web of Science ®Google Scholar
• Taylor D., Mir S., Mace S., Whiskey E. Co-prescribing of atypical and typical antipsychotics – prescribing sequence and documented outcome. Psychiatric Bulletin 2002; 26: 170–172
   Google Scholar
• Vieta E. Atypical antipsychotics in the treatment of mood disorders. Current Opinion in Psychiatry 2003; 16: 23–27
   Web of Science ®Google Scholar
• Wetterling T. Bodyweight gain with atypical antipsychotics. Drug Safety 2001; 24: 59–73
   PubMed Web of Science ®Google Scholar
• Wirshing D., Wirshing W. C., Marder S. R., Liberman R. P., Mintz J. Informed consent: Assessment of comprehension. American Journal of Psychiatry 1998; 155: 1508–1511
   PubMed Web of Science ®Google Scholar